WallStreetZenWallStreetZen

NASDAQ: VRDN
Viridian Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for VRDN

Based on 8 analysts offering 12 month price targets for Viridian Therapeutics Inc

Min Forecast
$22.00+7.47%
Avg Forecast
$33.00+61.21%
Max Forecast
$43.00+110.06%

Should I buy or sell VRDN stock?

Based on 8 analysts offering ratings for Viridian Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 37.5%
Buy
5 analysts 62.5%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although VRDN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates VRDN as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their VRDN stock forecasts and price targets.

VRDN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-22
lockedlocked$00.00+00.00%2026-08-07
lockedlocked$00.00+00.00%2026-06-30
lockedlocked$00.00+00.00%2026-06-30
lockedlocked$00.00+00.00%2026-06-29Find Out Why
Evercore ISI Group
Bottom 12%
12
BuyMaintains$26.00+27.02%2026-05-15
Goldman Sachs
Top 23%
78
Strong BuyMaintains$31.00+51.44%2026-04-07
HC Wainwright & Co.
Top 2%
99
BuyMaintains$22.00+7.47%2026-03-31

1 of 1

Forecast return on equity

Is VRDN forecast to generate an efficient return?

Company
18.82%
Industry
22.19%
Market
168.26%
VRDN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is VRDN forecast to generate an efficient return on assets?

Company
11.35%
Industry
23.8%
VRDN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

VRDN earnings per share forecast

What is VRDN's earnings per share in the next 3 years based on estimates from 17 analysts?

Avg 1 year Forecast
-$3.83
Avg 2 year Forecast
-$2.42
Avg 3 year Forecast
$0.04

VRDN revenue forecast

What is VRDN's revenue in the next 3 years based on estimates from 17 analysts?

Avg 1 year Forecast
$28.5M-59.95%
Avg 2 year Forecast
$236.1M+231.97%
Avg 3 year Forecast
$608.7M+755.85%
VRDN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

VRDN revenue growth forecast

How is VRDN forecast to perform vs Biotechnology companies and vs the US market?

Company
101.21%
Industry
30.84%
Market
13.9%
VRDN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
VRDN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

VRDN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
VRDN$20.47$33.00+61.21%Strong Buy
SLS$11.61N/AN/A
VERA$32.54$74.57+129.17%Strong Buy
MLYS$25.86N/AN/AStrong Buy
NRIX$23.01$34.67+50.66%Strong Buy
View Top Biotech Stocks

Viridian Therapeutics Stock Forecast FAQ

Is Viridian Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: VRDN) stock is to Strong Buy VRDN stock.

Out of 8 analysts, 3 (37.5%) are recommending VRDN as a Strong Buy, 5 (62.5%) are recommending VRDN as a Buy, 0 (0%) are recommending VRDN as a Hold, 0 (0%) are recommending VRDN as a Sell, and 0 (0%) are recommending VRDN as a Strong Sell.

If you're new to stock investing, here's how to buy Viridian Therapeutics stock.

What is VRDN's earnings growth forecast for 2026-2028?

(NASDAQ: VRDN) Viridian Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.

Viridian Therapeutics's earnings in 2026 is -$386,974,000.On average, 17 Wall Street analysts forecast VRDN's earnings for 2026 to be -$433,376,917, with the lowest VRDN earnings forecast at -$475,193,093, and the highest VRDN earnings forecast at -$378,282,886. On average, 17 Wall Street analysts forecast VRDN's earnings for 2027 to be -$274,507,168, with the lowest VRDN earnings forecast at -$371,938,519, and the highest VRDN earnings forecast at -$178,435,324.

In 2028, VRDN is forecast to generate $5,007,518 in earnings, with the lowest earnings forecast at -$255,360,774 and the highest earnings forecast at $433,003,052.

What is VRDN's revenue growth forecast for 2026-2028?

(NASDAQ: VRDN) Viridian Therapeutics's forecast annual revenue growth rate of 101.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.9%.

Viridian Therapeutics's revenue in 2026 is $71,127,000.On average, 17 Wall Street analysts forecast VRDN's revenue for 2026 to be $3,226,903,698, with the lowest VRDN revenue forecast at $1,153,655,175, and the highest VRDN revenue forecast at $12,966,300,187. On average, 16 Wall Street analysts forecast VRDN's revenue for 2027 to be $26,750,570,556, with the lowest VRDN revenue forecast at $12,601,499,081, and the highest VRDN revenue forecast at $57,423,319,465.

In 2028, VRDN is forecast to generate $68,965,535,831 in revenue, with the lowest revenue forecast at $35,972,561,253 and the highest revenue forecast at $169,145,357,617.

What is VRDN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: VRDN) forecast ROA is 11.35%, which is lower than the forecast US Biotechnology industry average of 23.8%.

What is VRDN's Price Target?

According to 8 Wall Street analysts that have issued a 1 year VRDN price target, the average VRDN price target is $33.00, with the highest VRDN stock price forecast at $43.00 and the lowest VRDN stock price forecast at $22.00.

On average, Wall Street analysts predict that Viridian Therapeutics's share price could reach $33.00 by Sep 22, 2027. The average Viridian Therapeutics stock price prediction forecasts a potential upside of 61.21% from the current VRDN share price of $20.47.

What is VRDN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: VRDN) Viridian Therapeutics's current Earnings Per Share (EPS) is -$3.39. On average, analysts forecast that VRDN's EPS will be -$3.83 for 2026, with the lowest EPS forecast at -$4.19, and the highest EPS forecast at -$3.34. On average, analysts forecast that VRDN's EPS will be -$2.42 for 2027, with the lowest EPS forecast at -$3.28, and the highest EPS forecast at -$1.58. In 2028, VRDN's EPS is forecast to hit $0.04 (min: -$2.25, max: $3.82).

What is VRDN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: VRDN) forecast ROE is 18.82%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.